Nivolumab plus chemotherapy prolonged survival of patients with advanced gastric, gastroesophageal junction, and esophageal cancers compared with chemotherapy.
Currently, fulvestrant plus palbociclib is approved by the FDA in the metastatic breast cancer setting only following disease progression on endocrine therapy.
The nongovernmental organizations argued that patents for this CAR-T should never have been granted in the first place because the underlying technology is not novel.
A new study examines the differences in access to novel therapies for European patients with cancer compared with patients in other geographic regions.
This phase 3 study compared endocrine therapy with or without abemaciclib in patients with high-risk, early-stage, hormone receptor-positive, HER2-negative breast cancer.
Compared with sunitinib alone, nivolumab plus cabozantinib therapy was associated with a 49% decreased risk for progression and 40% decreased risk for death.
Data from the CCC19 registry were evaluated to uncover risk factors associated with increased 30-day mortality in patients with cancer infected with COVID-19.
Treatment of some types of rare sarcomas with pembrolizumab resulted in durable clinical benefit for some patients. Partial response rates were highest in alveolar soft-part sarcoma.
There was no benefit to adding palbociclib to adjuvant endocrine therapy for treatment of early HR+, HER2- breast cancer vs endocrine therapy alone, according to a results from PALLAS.
Durvalumab plus tremelimumab added to chemotherapy did not improve survival or response in metastatic pancreatic cancer, according to results of a phase 2 trial.
